Company Overview

Aldeyra Therapeutics, Inc. is a U.S.-based biotechnology company focused on developing therapies designed to treat immune-mediated and metabolic diseases, particularly those involving inflammation and retinal disorders. The company operates within the biopharmaceutical industry and primarily concentrates on discovering and commercializing small-molecule therapies that target reactive aldehyde species (RASP), which are implicated in inflammatory and systemic disease pathways. Aldeyra’s development programs have historically focused on ophthalmology indications such as dry eye disease, allergic conjunctivitis, and retinal disease, alongside selected systemic inflammatory conditions.

The company’s primary value drivers are its clinical-stage drug candidates, intellectual property portfolio, and regulatory advancement pipeline. Key investigational assets have included reproxalap for ocular inflammatory diseases and ADX-2191 for retinal indications. Aldeyra was founded in 2004 and became publicly traded on Nasdaq under the ticker ALDX. Over time, the company evolved from an early-stage research platform into a clinical-stage biotechnology company with multiple programs evaluated in late-stage clinical trials and interactions with the U.S. Food and Drug Administration through formal regulatory submission processes documented in SEC filings and company disclosures.

Business Operations

Aldeyra primarily operates as a single-segment clinical-stage biotechnology company focused on research, development, and potential commercialization of proprietary therapeutics. Revenue generation has historically been limited because the company has not yet broadly commercialized approved products; operations have therefore largely been financed through public equity offerings, collaborations, and cash reserves. The company’s principal business activities include drug discovery, clinical development, regulatory engagement, intellectual property management, and outsourced manufacturing coordination through contract research and manufacturing organizations.

The company’s pipeline has centered on proprietary RASP-modulating compounds and ophthalmic therapeutics. Important development programs have included reproxalap, investigated for dry eye disease and allergic conjunctivitis, and ADX-2191, evaluated for retinal diseases including retinitis pigmentosa and proliferative vitreoretinopathy. Aldeyra conducts operations primarily in the United States while utilizing global clinical trial sites and third-party vendors for portions of research, manufacturing, and development support. Public filings and investor materials indicate the company relies heavily on strategic scientific collaborations and external clinical infrastructure rather than vertically integrated manufacturing assets.

Strategic Position & Investments

Aldeyra’s strategic direction has focused on advancing differentiated anti-inflammatory and retinal disease therapies through late-stage clinical development and potential regulatory approval. The company has emphasized diseases with unmet medical need, particularly ophthalmic conditions where existing therapies may have limitations related to efficacy, tolerability, or treatment duration. Its strategy has included leveraging the RASP modulation platform as a potentially distinct mechanism targeting inflammatory signaling pathways.

The company has invested substantially in clinical development programs, regulatory submissions, and intellectual property expansion tied to its lead candidates. Public disclosures indicate continued investment in ophthalmology as a core therapeutic area, including dry eye disease and retinal indications. Aldeyra has also explored broader inflammatory disease applications for its technology platform. While the company has not been widely associated with major transformative acquisitions compared with larger pharmaceutical peers, it has maintained strategic relationships with research organizations and clinical development partners supporting pipeline advancement. Data regarding significant portfolio company ownership or large-scale joint ventures is limited in publicly available sources.

Geographic Footprint

Aldeyra is headquartered in Lexington, Massachusetts, within the biotechnology corridor of the United States. The company’s operational and executive activities are primarily U.S.-based, including corporate management, regulatory strategy, and investor relations. Clinical and development activities have nevertheless involved multi-site trial operations extending into international regions through contracted research organizations and study investigators.

The company’s principal commercial focus remains the United States ophthalmology market, particularly through engagement with the FDA regulatory framework. Although Aldeyra does not currently maintain the extensive international commercial infrastructure typical of multinational pharmaceutical companies, its clinical development programs and intellectual property strategy position it for potential broader market participation in North America, Europe, and selected global ophthalmology markets if future approvals and commercialization efforts expand internationally.

Leadership & Governance

Aldeyra’s leadership team is composed of biotechnology and pharmaceutical executives with backgrounds in clinical medicine, drug development, ophthalmology, finance, and corporate operations. The company was founded by Todd C. Brady, M.D., Ph.D., who has played a central role in shaping its scientific and strategic direction. Public company governance is overseen by a board of directors and executive leadership team consistent with Nasdaq-listed biotechnology company standards.

The company’s leadership philosophy, as reflected in public statements, investor communications, and regulatory filings, emphasizes targeted innovation in immune-mediated disease, disciplined clinical execution, and the development of therapies addressing unmet medical needs in ophthalmology and inflammation.

• Todd C. Brady, M.D., Ph.D. – President and Chief Executive Officer
• Stephen L. Daly, CPA – Chief Financial Officer
• Richard W. Liscinski – Chief Operating Officer
• Keith C. Berman – Director and Chairman of the Board
• Ralph S. Tyler – Senior Vice President, Legal and General Counsel